Last ¥1,707 JPY
Change Today +9.50 / 0.56%
Volume 7.0M
4503 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 1:00 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (4503) Snapshot

Open
¥1,700
Previous Close
¥1,698
Day High
¥1,715
Day Low
¥1,692
52 Week High
11/4/14 - ¥1,842
52 Week Low
04/14/14 - ¥1,062
Market Cap
3.9T
Average Volume 10 Days
9.3M
EPS TTM
--
Shares Outstanding
2.3B
EX-Date
03/27/15
P/E TM
--
Dividend
¥30.00
Dividend Yield
1.64%
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., and Dana-Farber Cancer Institute. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

astellas pharma inc (4503) Key Developments

Astellas Opens Regional Office in Dubai

Astellas has announced the opening of a regional headquarters in Dubai and the launch of a new strategy for the Middle East and Africa. The company is to use the new office as a staging post to market its products across the region, especially Ghana, Morocco, Nigeria, and Tunisia. Astellas is also to collect data on prostate cancer and leukaemia in the UAE with the aim of launching oncology medicines there. Within five years Astellas may be manufacturing drugs and conducting clinical trials in the UAE.

Proteostasis Therapeutics and Astellas Pharma Enter Worldwide Collaboration Agreement

Proteostasis Therapeutics and Astellas Pharma have entered into a worldwide collaboration agreement for the discovery, screening, and clinical development of potential therapeutic candidates that target the unfolded protein response (UPR) cellular mechanism. By leveraging Proteostasis's proprietary disease relevant translation and Proteostasis network platform, candidates will be identified as potential therapeutic agents to treat one undisclosed genetic disease, as well as the potential to explore additional indications known to be modulated by the UPR pathway. Once a candidate is selected, Proteostasis will have the option for co-development with Astellas globally, and will co-promote the potential therapy in the United States. Based on the terms of the agreement, Proteostasis will receive an upfront payment, as well as a securities investment from Astellas, and will be eligible for additional payments for financing research and achieving certain development and commercial milestones that total USD 400 million, in addition to tiered royalties on sales. Furthermore, Astellas will have the option to initiate two other programmes under the same agreement conditions, which could raise the cumulative potential value of the deal to USD 1.2 billion. The partnership will be managed by Astellas's Innovation Management arm. Proteostasis is focused on the development of novel therapeutics that treat disorders caused by defects in protein folding, trafficking, and clearance. The misfolding and accumulation of unfolded proteins is implicated in a variety of diseases that are referred to as protein conformational diseases, including genetic diseases, neurodegenerative conditions such as Alzheimer's and Parkinson's diseases, as well as retinal degenerative diseases. Modulation of the UPR system that typically responds to this type of protein-misfolding situation in the endoplasmic reticulum could improve the stress response and restore function within the cell. UPR modulators could offer a novel disease-modifying treatment option for disorders and conditions that currently have no effective treatment or cure. Meanwhile, the partnership will benefit from Astellas's extensive experience in clinical development that will probably expedite the process of potentially bringing new UPR modulators to market.

Dana-Farber Cancer Institute and Astellas Announce Research Collaboration

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer. K-Ras is the most commonly mutated oncogene in human cancers, with about 30% of all cancers harbouring activating rasmutations. Furthermore, cancers with a high prevalence of K-Ras mutations, such as lung cancer and pancreatic cancer, are difficult to treat and clinical outcomes are poor even with aggressive medical interventions. Despite more than 20 years of research by industry and academia, K-Ras has proven highly difficult to target and no effective therapy currently exists.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4503:JP ¥1,707.00 JPY +9.50

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $140.33 USD -0.93
CSL Ltd A$82.57 AUD -0.45
Mylan Inc/PA $58.61 USD -0.01
Takeda Pharmaceutical Co Ltd ¥4,972 JPY +31.50
Valeant Pharmaceuticals International Inc C$166.40 CAD -1.14
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 31.5x
Price/Sales 3.0x
Price/Book 2.7x
Price/Cash Flow 21.6x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.